Importantly, these data strongly support the possibility of targeting CXCR4 on CSCs and tumor cells not only to reduce the tumor mass but also to impair tumor regeneration and possibly resistance to therapy, improving the success of cancer therapy by using both challenging and opportunistic strategies. The gene discussed is CXCR4; the disease is neoplasm.